Imaging Biometrics
IB DCE calculates parameters for solid tumor perfusion and permeability analysis. IB DCE includes the Tofts, Extended Tofts, and Patlak models. IB DCE can be used to monitor tumor response to antiangiogenic and vascular disrupting agents, radiotherapy, and chemotherapy.
Information source: Vendor
Last updated: July 31, 2020

General Information

Product name IB DCE
Company Imaging Biometrics
Subspeciality Multiple
Modality MR
Disease targeted Tumors
Key-features Automated generation of perfusion parameter maps and Vascular Input Function, anatomical image registration, report generation
Suggested use

Technical Specifications

Data characteristics
Input Dynamically acquired DCE datasets
Input format DICOM
Output Quantitative output of multi-parameter DCE maps
Output format DICOM
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Hybrid solution
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 10 - 60 seconds


Certified, Class I , MDD
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)


Market presence
On market since 01-2013
Distribution channels Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, aycan Medical Systems, Pixmeo, Calantic
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use, Subscription
Based on Number of users, Number of installations, Number of analyses


Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers